PharmAthene, Inc. (NYSE:PIP) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,387,922 shares, a decline of 17.4% from the November 15th total of 1,680,280 shares. Based on an average daily volume of 1,245,748 shares, the short-interest ratio is presently 1.1 days. Approximately 2.3% of the shares of the company are sold short.
Separately, TheStreet raised PharmAthene from a “hold” rating to a “buy” rating in a report on Wednesday, November 30th.
PharmAthene (NYSE:PIP) opened at 3.20 on Friday. The company’s 50-day moving average price is $2.95 and its 200-day moving average price is $2.65. PharmAthene has a one year low of $1.38 and a one year high of $3.30. The firm has a market cap of $213.53 million and a price-to-earnings ratio of 1.81.
The firm also recently disclosed a special dividend, which will be paid on Friday, February 3rd. Shareholders of record on Sunday, January 24th will be paid a dividend of $2.91 per share. The ex-dividend date is Monday, February 6th.
In other news, major shareholder Prescott Group Capital Managem sold 1,354,632 shares of the business’s stock in a transaction that occurred on Friday, December 9th. The stock was sold at an average price of $3.26, for a total value of $4,416,100.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
WARNING: This piece was first reported by Mideast Time and is owned by of Mideast Time. If you are viewing this piece on another site, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this piece can be accessed at http://www.mideasttime.com/pharmathene-inc-pip-short-interest-update/1444311.html.
Pharmathene, Inc (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company’s anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes.
Receive News & Ratings for PharmAthene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmAthene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.